alexa Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Thyroid Disorders & Therapy

Author(s): Carayon P, ThomasMorvan C, Castanas E, Tubiana M

Abstract Share this page

Abstract To characterize the relationship of the TSH receptor-adenylate cyclase system to differentiation in human thyroid cancers, adenylate cyclase and TSH binding were studied in membranes from primary and metastatis thyroid carcinomas of varying histological types (n = 33) and normal thyroids (n = 12). Membranes from differentiated carcinomas (n = 23) exhibit wide patient to patient variability; some membranes show entirely normal adenylate cyclase and TSH-binding characteristics, and other membranes exhibit decreased TSH stimulation of adenylate cyclase which is accompanied by either a normal or decrease TSH-binding site concentration. With respect to the TSH-binding site concentration and TSH stimulation of the adenylat cyclase, the well differentiated carcinomas are not significantly different from normal thyroids, whereas the moderately differentiated and the papillary carcinomas are significantly different (P < 0.001 and P < 0.001, respectively). Membranes from undifferentiated carcinomas (n = 5) and those from medullary carcinomas (n = 5) are characterized by an absence of both TSH binding and TSH stimulation of the adenylate cyclase. In conclusion, while a general relationship exists between the impairment of TSH responsiveness and the dedifferentiation process, no pattern of membrane alteration is specific for any histological type. This article was published in J Clin Endocrinol Metab and referenced in Journal of Thyroid Disorders & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

  • Ildiko Molnar
    The role of tissue-specific type 2 5’-deiodinase enzyme activities in Graves’ orbitopathy and systemic sclerosis: a new candidate in thyroid autoimmunity
    PDF Version
  • Ildikó Molnár
    Characteristics of allergy in autoimmune thyroid diseases
    PPT Version | PDF Version
  • Paul J. Davis
    Nanotetrac targets the thyroid hormone receptor on integrin αvβ3 on tumor cells to promote apoptosis, disorder cell defense pathways and block angiogenesis
    PPT Version | PDF Version
  • A Martin Gerdes
    Wrong about β-blockers! Wrong about positive inotropes! Wrong about Thyroid Hormone treatment of Heart Failure?
    PDF Version

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords